The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.
Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.
Moderna Inc (MRNA) is the sponsoring company for this trial. BiotechSign currently grades this company C (59/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.